Stockscreener 앱 받기
6.84
11.86%
-0.92
시간 외 거래:
7.24
0.40
+5.85%
전일 마감가:
$7.76
열려 있는:
$7.84
하루 거래량:
3.16M
Relative Volume:
3.00
시가총액:
$501.59M
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
-3.4372
EPS:
-1.99
순현금흐름:
$-64.37M
1주 성능:
-23.75%
1개월 성능:
+3.48%
6개월 성능:
-16.79%
1년 성능:
+164.09%
1일 변동 폭
$6.80
$7.8457
1주일 범위
$6.80
$9.85
52주 변동 폭
$2.54
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
명칭
Mind Medicine Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
MNMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MNMD | 6.84 | 501.59M | 11.40B | -95.73M | -64.37M | -1.99 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Mind Medicine Inc 주식(MNMD)의 최신 뉴스
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Mind Medicine (MindMed) Sees Unusually High Options Volume (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed (MNMD) to Present at Major Healthcare Investor Conferences in London, Florida | MNMD Stock News - StockTitan
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... - Yahoo Finance
MindMed Advances Phase 3 Trials in Mental Health - TipRanks
Certain Restricted Stock Units of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
Certain Common Stock of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
MindMed Reports Third Quarter 2024 Financial Results and Business Updates - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.1%What's Next? - MarketBeat
(MNMD) Trading Report - Stock Traders Daily
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine (MindMed) (MNMD) to Release Quarterly Earnings on Thursday - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
MNMDMind Medicine (MindMed) Inc. Common Shares Latest Stock News & Market Updates - StockTitan
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update - The Globe and Mail
FDA is said to see “path forward” for ecstasy-based drug (DRUG:NASDAQ) - Seeking Alpha
MindMed announces exchange agreement with investors By Investing.com - Investing.com
Bright Minds rally ends as psychedelic stocks extend volatility - MSN
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
(MNMD) Investment Analysis and Advice - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated at Leerink Partners - MarketBeat
Mind Medicine assumed with an Outperform at Leerink - Yahoo Finance
Stroke-recovery device using brain-computer interface receives FDA market authorization | WashU Medicine - WashU Medicine
Trend Tracker for (MNMD) - Stock Traders Daily
"TNT Radio" Jeff Ghaemaghamy on Mind Medicine with Charles Kovess28 January 2024 (Podcast Episode 2024)News - imdb
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Marshall Wace LLP Has $15.58 Million Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine's chief medical officer sells shares worth over $41,000 - Investing.com India
MindMed executive sells over $26k in company stock By Investing.com - Investing.com South Africa
Mind Medicine's chief medical officer sells shares worth over $41,000 By Investing.com - Investing.com UK
Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma - Barchart
Rhumbline Advisers Makes New $679,000 Investment in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Generalized Anxiety Disorder Global Market is Booming Across - openPR
(MNMD) Proactive Strategies - Stock Traders Daily
Mankind Pharma: Rs 10000 crore fund raise via this routeDetails - ET Now
Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18
Mind Medicine Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):